Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.
about
Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategiesPrevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovirViral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.Tribute to Mark WainbergPharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeysReversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.Chemoprophylaxis for HIV prevention: new opportunities and new questions.Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338).Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.The impact of the M184V substitution on drug resistance and viral fitness.Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.Retrovirus reverse transcriptases containing a modified YXDD motif.Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophageRole of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV.CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.HIV-1 replicative fitness in elite controllers.Tackling HIV and AIDS: contributions by non-human primate models.Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy.Role of Monocyte/Macrophages during HIV/SIV Infection in Adult and Pediatric Acquired Immune Deficiency Syndrome.Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART).
P2860
Q26825814-8E65E53F-7D76-4C7E-A0CF-FA15C80B3C55Q28472146-0A66FB7B-62C2-401F-A377-FF20ABEFBA63Q33644248-CC0CED1C-73DA-41BA-B61E-1D2B083539C9Q33843148-978B24EB-DA3F-4BCE-8200-E4ABF2E6ECA8Q33846297-75359376-A0BA-488E-A998-E9920D97F6C2Q33883757-E41C5ED0-4014-4B4C-ABCF-29782DE1CEE6Q34465037-79FCAAE1-99C5-4EFD-A97B-F522D451EBE3Q34716901-174E9995-EFE3-4B6A-A70E-CE095AAB1C1BQ34786284-4362C24A-7C4E-4891-8C81-99529468D571Q35566910-D42916D2-C9C6-434A-8DD8-5380A856109AQ35619304-E8F405CC-1BD2-4DC3-BD41-9A08A01CBCEAQ35647376-25C0418E-2E4F-4512-A04A-235CE2A38A6BQ35752812-462CA697-701A-4A0A-9156-7C4AFDB3250AQ35917349-915BE6E9-E22D-4A49-8918-77E47B2EDE9CQ36172536-149BA468-26B5-4581-9A93-7EDB68CC256DQ36186797-AAE3912B-6687-4D42-B640-F64ED47A7A92Q36246775-3D7E3324-64DF-48B6-BCF9-777D8B68101DQ36727259-08C5BCA2-C112-4C99-8EDD-4B37926498E2Q37093847-B5A99FED-EFBC-4C28-A0CA-0E15157F97F7Q37489188-164C7739-4667-429F-A9B9-A53DED6A94D6Q37538534-884F3A81-8BB1-4410-A2C7-ECCBD39B2450Q37730097-B4A3654A-EBAC-413D-A5AE-49A69A66BCABQ37856676-F59AAE63-E085-4DB8-B5A1-AB2286C91177Q40191155-2935D1C4-E5CE-44BC-A981-3212175F157EQ40721745-8796F271-CF81-42AB-94DB-D92215785856Q45326424-EE0EDFB4-49AA-418B-AC53-857B4DACA370Q47100536-4D9B4078-82FF-485C-AD13-2452559C3051Q50357334-FAF20E32-273A-4095-84E5-15B197A58CC7
P2860
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Virulence and reduced fitness ...... tion in reverse transcriptase.
@ast
Virulence and reduced fitness ...... tion in reverse transcriptase.
@en
Virulence and reduced fitness ...... tion in reverse transcriptase.
@nl
type
label
Virulence and reduced fitness ...... tion in reverse transcriptase.
@ast
Virulence and reduced fitness ...... tion in reverse transcriptase.
@en
Virulence and reduced fitness ...... tion in reverse transcriptase.
@nl
prefLabel
Virulence and reduced fitness ...... tion in reverse transcriptase.
@ast
Virulence and reduced fitness ...... tion in reverse transcriptase.
@en
Virulence and reduced fitness ...... tion in reverse transcriptase.
@nl
P2093
P2860
P1433
P1476
Virulence and reduced fitness ...... tion in reverse transcriptase.
@en
P2093
Don R Canfield
Joanne Higgins
Koen K A Van Rompay
Mark A Wainberg
Niels C Pedersen
Ross P Tarara
Thomas W North
Tim B Matthews
P2860
P304
P356
10.1128/JVI.76.12.6083-6092.2002
P407
P577
2002-06-01T00:00:00Z